Ranibizumab in Idiopathic Parafoveal Telangiectasia (RIPT) Trial
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This research is being done to look at the effects of an experimental drug, ranibizumab, for
the treatment of a condition called "idiopathic parafoveal telangiectasia" or IPT. IPT is
caused by swelling in the retina (the light sensitive tissue in the back of the eye) due to
leaky blood vessels in this area. Swelling in the retina can lead to blurry vision.